1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Lymphangioleiomyomatosis - Pipeline Review, H2 2014

Lymphangioleiomyomatosis - Pipeline Review, H2 2014

  • July 2014
  • -
  • Global Markets Direct
  • -
  • 41 pages

Lymphangioleiomyomatosis - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Lymphangioleiomyomatosis - Pipeline Review, H2 2014’, provides an overview of the Lymphangioleiomyomatosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lymphangioleiomyomatosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lymphangioleiomyomatosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lymphangioleiomyomatosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Lymphangioleiomyomatosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Lymphangioleiomyomatosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lymphangioleiomyomatosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lymphangioleiomyomatosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lymphangioleiomyomatosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Lymphangioleiomyomatosis - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lymphangioleiomyomatosis Overview 6
Therapeutics Development 7
Pipeline Products for Lymphangioleiomyomatosis - Overview 7
Pipeline Products for Lymphangioleiomyomatosis - Comparative Analysis 8
Lymphangioleiomyomatosis - Therapeutics under Development by Companies 9
Lymphangioleiomyomatosis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Lymphangioleiomyomatosis - Products under Development by Companies 13
Lymphangioleiomyomatosis - Companies Involved in Therapeutics Development 14
AstraZeneca PLC 14
Novartis AG 15
Circadian Technologies Limited 16
Therametrics holding AG 17
Nobelpharma Co., Ltd. 18
Lymphangioleiomyomatosis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
sirolimus - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
everolimus - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
VGX-200 Series - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
DasKloster-0080-01 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Small Molecule to Inhibit Src Tyrosine Kinase for Lymphangioleiomyomatosis - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Lymphangioleiomyomatosis - Recent Pipeline Updates 35
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables

Number of Products under Development for Lymphangioleiomyomatosis, H2 2014 7
Number of Products under Development for Lymphangioleiomyomatosis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Lymphangioleiomyomatosis - Pipeline by AstraZeneca PLC, H2 2014 14
Lymphangioleiomyomatosis - Pipeline by Novartis AG, H2 2014 15
Lymphangioleiomyomatosis - Pipeline by Circadian Technologies Limited, H2 2014 16
Lymphangioleiomyomatosis - Pipeline by Therametrics holding AG, H2 2014 17
Lymphangioleiomyomatosis - Pipeline by Nobelpharma Co., Ltd., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Lymphangioleiomyomatosis Therapeutics - Recent Pipeline Updates, H2 2014 35

List of Figures

Number of Products under Development for Lymphangioleiomyomatosis, H2 2014 7
Number of Products under Development for Lymphangioleiomyomatosis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 12
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Top 10 Target, H2 2014 20
Number of Products by Stage and Top 10 Target, H2 2014 21
Number of Products by Top 10 Mechanism of Action, H2 2014 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 23
Number of Products by Stage and Top 10 Route of Administration, H2 2014 24
Number of Products by Top 10 Molecule Type, H2 2014 25
Number of Products by Stage and Top 10 Molecule Type, H2 2014 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • August 2016
  • by GBI Research

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation Summary Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Obesity Statistics in the US

  • November 2016
    40 pages
  • Obesity  

    Vaccine  

  • United States  

    North America  

    World  

View report >

Digestive System Disorder Statistics in the US and the UK

  • November 2016
    12 pages
  • Digestive Syste...  

  • United States  

    United Kingdom  

View report >

Related Market Segments :

Therapy
Research And Development

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.